Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 – Existing Angiogenics Retain Dominance Though High Unmet Need Remains...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Macular Degeneration Asia-Pacific Market to 2019 – Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 11
2.3.1 Disease Initiation 12
2.3.2 Disease Propagation 12
2.4 Classification 14
2.4.1 Early AMD 14
2.4.2 Intermediate AMD 14
2.4.3 Advanced AMD 15
2.5 Co-morbidities and Complications 16
2.6 Diagnosis 17
2.6.1 History 17
2.6.2 Examination 17
2.6.3 Diagnostic Tests 18
2.7 Epidemiology 20
2.8 Prognosis and Disease Staging 22
2.9 Treatment Options 22
2.9.1 Pharmacological 22
2.9.2 Treatment Algorithms and Prescribing Habits 24
2.9.3 Non-pharmacological Care 26
3 Macular Degeneration Asia-Pacific Market to 2019 – Marketed Products 28
3.1 Therapeutic Landscape 29
3.1.1 Lucentis (ranibizumab) – Novartis AG/Roche (Genentech) 29
3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/Bayer Healthcare 30
3.1.3 Avastin (bevacizumab) – Genentech (Roche) 32
3.1.4 Macugen (pegaptanib sodium) – Valeant Pharmaceuticals/Pfizer 32
3.1.5 Visudyne (verteporfin injection) – Novartis AG 33
3.1.6 Triamcinolone Acetonide 34
3.2 Comparative Efficacy and Safety 35
4 Macular Degeneration Asia-Pacific Market to 2019 – Pipeline for Disease 37
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 39
4.3 Pipeline Analysis by Mechanism of Action 41
4.4 Clinical Trials 43
4.4.1 Failure Rate 43
4.4.2 Clinical Trial Duration 44
4.4.3 Clinical Trial Size 45
4.5 Promising Drug Candidates in the Pipeline 46
4.5.1 MC-1101 – MacuCLEAR, Inc. 46
4.5.2 KH902 (Fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 46
5 Macular Degeneration Asia-Pacific Market to 2019 – Market Forecast to 2019 48
5.1 Geographical Markets 48
5.1.1 APAC Market 48
5.1.2 Australia 50
5.1.3 China 52
5.1.4 India 54
5.1.5 Japan 56
5.2 Drivers and Barriers for the Disease Market 58
5.2.1 Drivers 58
5.2.2 Barriers 59
6 Macular Degeneration Asia-Pacific Market to 2019 – Deals and Strategic Consolidations 60
6.1 Deals Analysis 60
6.2 Major Co-development Deals 62
6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR 62
6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners 63
6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD 63
6.2.4 Alcon Enters into Collaboration with AstraZeneca 63
6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429 63
6.3 Major Licensing Deals 64
6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy 65
6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners 65
6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma 65
6.3.4 Lpath Enters into Licensing Agreement with Pfizer 65
6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science 66
7 Macular Degeneration Asia-Pacific Market to 2019 – Appendix 67
7.1 All Pipeline Drugs by Phase 67
7.1.1 Discovery 67
7.1.2 Preclinical 68
7.1.3 IND-filed and Phase 0 69
7.1.4 Phase I 69
7.1.5 Phase II 70
7.1.6 Phase III 70
7.1.7 Undisclosed 71
7.2 Market Forecasts to 2019 71
7.2.1 Asia-Pacific 71
7.2.2 Australia 71
7.2.3 China 72
7.2.4 India 72
7.2.5 Japan 72
7.3 Market Definitions 73
7.4 Abbreviations 73
7.5 References 75
7.6 Research Methodology 77
7.6.1 Coverage 77
7.6.2 Secondary Research 77
7.6.3 Primary Research 77
7.6.4 Therapeutic Landscape 78
7.6.5 Geographical Landscape 81
7.6.6 Pipeline Analysis 81
7.7 Expert Panel Validation 81
7.8 Contact Us 81
7.9 Disclaimer 81